BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36813626)

  • 1. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
    Tinsley-Vance SM; Ali NA; Ball S; Aguirre LE; Jain AG; Hussaini MO; Chan O; Kuykendall A; Sweet K; Lancet J; Padron E; Sallman DA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):355-359. PubMed ID: 36813626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
    Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
    GenoMed4All consortium
    Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
    Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
    Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
    Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation between U2AF1 Gene Mutation Characteristics and Clinical Manifestations and Prognosis in Patients with Myelodysplastic Syndrome].
    Zhao WS; Zhang YT; Jiang QL; Liu QF; Dai M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1977-1984. PubMed ID: 33283729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X; Song X; Yan X
    Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
    Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
    [No Abstract]   [Full Text] [Related]  

  • 11. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
    Nagehan P; Sabbir M; Song J; Mohammad H
    J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high frequency of the U2AF1 S34Y mutation and its association with isolated trisomy 8 in myelodysplastic syndrome in Asians, but not in Caucasians.
    Kim SY; Kim K; Hwang B; Im K; Park SN; Kim JA; Hwang SM; Bang D; Lee DS
    Leuk Res; 2017 Oct; 61():96-103. PubMed ID: 28938223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of
    Li B; Zou D; Yang S; Ouyang G; Mu Q
    J Int Med Res; 2020 Mar; 48(3):300060519891013. PubMed ID: 31826693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
    Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
    Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
    Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
    Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
    Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
    Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
    Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.